Compare Huntington Ingalls Industries Inc (HII) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Incyte Corporation — how do they compare? Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 2.2× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Incyte Corporation for 33 Days on average.
| HII | INCY | |
|---|---|---|
Market Cap | $10.44B | $22.85B |
Volume | 440,462 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $453.73 | $129.93 |
52-Week Low | $257.05 | $83.80 |
Typical Hold Time | 28 Days | 33 Days |
Enterprise Value | $13.37B | $18.35B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.80, up 1.58% today, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 15.78, net income margin of 5.01%, and a $57.3 billion backlog supporting revenue visibility. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, highlight operational momentum amid consistent earnings beats.
The outlook is supported by strong defense budgets and execution, but risks include project delays and macroeconomic pressures. Analysts are generally positive with a $363.67 consensus target, implying significant upside, though technical indicators suggest near-term caution.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
